Depo-Provera MDL 3140 Update: Settlement Talk Does Not End the Work for Meningioma Claimants

Bymasstortameric

Some Depo-Provera articles are starting to sound as if the case is already wrapped up. It is not that simple.

Here is where things stand as of this July update. The federal Depo-Provera brain tumor cases are in MDL No. 3140, in the Northern District of Florida, before Judge M. Casey Rodgers. The JPML's July 1, 2026 report identifies the proceeding by its full name: In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation. Recent litigation reporting says the MDL had grown to about 5,830 pending federal cases by July 1.

That number is big. Still, it does not answer the question a woman at her kitchen table is probably asking: "I took the shot years ago, and then I was diagnosed with a meningioma. What should I do now?"

Our answer is practical. Do not assume you are covered by settlement talk. Do not assume you are too late, either. Get the records together and have the timeline looked at.

The June settlement news, in plain English

On June 15, 2026, plaintiffs' leadership and Pfizer reportedly told the MDL court they had reached a global agreement in principle for eligible federal MDL claims. After that, the court vacated deadlines connected to the first bellwether trial.

That is real movement. It is also not the same as a public claims packet landing in every mailbox.

As of the sources reviewed for this article, the public reporting still has not laid out final payment tiers, proof rules, deadlines, releases, lien handling, or the exact process for women who have not filed. A general-causation and preemption hearing was reset for July 27, 2026 while the parties continued working on settlement documents.

So yes, the case may be moving toward resolution. But a headline about an agreement in principle should not be treated as a guarantee that every possible claim is safely included.

Why the label history is part of the story

Depo-Provera is the brand name for injectable medroxyprogesterone acetate. The FDA's Drugs@FDA database lists Pfizer for NDA 020246 and shows the original U.S. approval date as October 29, 1992 for the 150 mg/mL injectable contraceptive.

The same FDA database shows a December 12, 2025 labeling supplement for Depo-Provera. Litigation updates have described that change as the point when a U.S. meningioma warning was added.

For families, that may feel like dry regulatory history. In a warning case, it can matter. Lawyers are looking at when the injections happened, what the label said at that time, what information was available outside the United States, and whether patients and doctors had a fair warning before a diagnosis.

What science is being talked about

The main studies being discussed are not rumors.

A French study published in BMJ in 2024 reported an association between prolonged use of injectable medroxyprogesterone acetate and surgery for intracranial meningioma. The adjusted odds ratio was reported around 5.55.

A later Cleveland Clinic-related study, discussed in 2025 updates, looked at a very large health-system dataset and reported an increased relative risk.

Those findings are serious. They also do not decide any one person's claim by themselves. A case still turns on the medical chart, the number and timing of injections, the tumor diagnosis, treatment history, and other possible risk factors.

Records worth saving now

If this sounds like your situation, start with paper and portal records. Memory helps, but records carry the claim.

Try to gather:

  • Depo-Provera injection records, pharmacy records, or clinic notes;
  • OB-GYN, county clinic, primary-care, student-health, or Planned Parenthood records;
  • the rough dates of first and last use;
  • the approximate number of injections;
  • MRI or CT reports;
  • neurosurgery, pathology, radiation-oncology, and follow-up records;
  • the date the meningioma was first found; and
  • notes about symptoms, monitoring, surgery, radiation, or other treatment.

Do not panic if there are gaps. Older contraceptive records can be scattered. A review can often start with what you have and then identify what is missing.

Why waiting can be risky

Large settlements often create a false sense of calm. People hear "agreement" and think there is nothing left to do.

But an agreement in principle may be limited to certain filed federal cases. State-court cases may need a different process. Unfiled claims may face separate deadlines. Claims with missing proof may be handled differently. None of that should be guessed at from a headline.

It is also too early to responsibly promise a payment amount. Diagnosis, treatment, tumor location, duration of use, age, proof, liens, and final settlement rules can all affect an individual result.

The bottom line

The Depo-Provera meningioma litigation is moving fast. The MDL is large. The parties have reported progress. Key legal and scientific issues are still part of the court calendar while settlement documents are being worked out.

If you used Depo-Provera and were later diagnosed with a meningioma, the safest move is not to wait for internet chatter to clear things up. Save your records, write down your injection history while you still remember it, and ask for a case-specific review.

Mass Tort America provides information and attorney advertising. This article is not legal advice and does not create an attorney-client relationship. Every claim is fact-specific, and no attorney can guarantee compensation or a particular outcome.

Similar Posts